


PHARMACEUTICAL 2023

CymaBay Therapeutics Inc. Rank 333 of 446









PHARMACEUTICAL 2023



CymaBay Therapeutics Inc. Rank 333 of 446

The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 35% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -36%, being 79% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	138,073
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,441
Liabilities, Non-Current	30
Other Assets	3,078
Other Compr. Net Income	-313
Other Expenses	0
Other Liabilities	90,227
Other Net Income	-12,890
Other Revenues	0
Property and Equipment	701
Research and Development	67,995
Selling, General and Administrative Expense	25,116

Output Variable	Value in 1000 USD
Assets	141,852
Liabilities	105,698
Expenses	93,111
Revenues	0
Stockholders Equity	36,154
Net Income	-106,001
Comprehensive Net Income	-106,158
Economic Capital Ratio	-36%

